LDS/Medical Tests/Hereditary Dilated Cardiomyopathy Gene Mutation Panel, NGS

Hereditary Dilated Cardiomyopathy Gene Mutation Panel, NGS

Hypertrophic cardiomyopathy gene mutation analysis panel targets many different genes simultaneously for the diagnosis of inherited hypertrophic cardiomyopathy. It targets most common sarcomeric genes that are associated with HCM (MYBPC3, MYL2, MYL3, MYH7, ACTC, TPM1, TNNI3, TNNC1, TNNT2), as well as genes encoding Z-disk, cytoskeletal and other non-sarcomeric proteins (ACTN2, CSPR3, MYOZ, NEXN2, PLN, GLA, LAMP2, PRKAG2, and TTR). This proteins makeup heart structure and signaling network regulating the function of each cardiomyocyte or heart muscle.

Hypertrophic cardiomyopathy (HCM) is a heterogeneous disorder of the myocardium described as an unexplained left ventricular (LV) hypertrophy (thickening) associated with non-dilated ventricular chambers in the absence of other cardiac or systemic disorders in sufficient amounts capable of producing (LV) hypertrophy. The diagnosis is suspected when a patient demonstrates a left ventricular thickness that is ≥15 mm in adults, ≥13 mm in a relative inherited from the family's pathogenic sarcomere variant, or from a z-score >3 in children. Pathological features include myocardial fiber hypertrophy, disorganized myocardial cells, interstitial fibrosis and thickened intra-myocardial coronary vessels. The majority of HCM patients are asymptomatic. Only about 25% develop symptom such as dyspnea, syncope, palpitations, and chest pain. The disorder has inter- and intra-familial variability ranging from benign cases to malignant forms with a high risk of cardiac failure and sudden cardiac death. It is the most common cause of sudden cardiac death in young people with an estimated prevalence of 1:500 in the general adult population. HCM can be sporadic but is mostly commonly inherited as an autosomal dominant trait. It can be divided into myofilament (sarcomeric) HCM, Z-disk HCM, and calcium-handling HCM.

The primary defect of HCM occurs in the sarcomere, composed of thick and thin filaments and the Z disks. A change in the amino acid sequence in the sarcomere protein or a deficiency of a sarcomere protein instigates a series of initial defects, such as altered levels of the sarcomere protein, calcium sensitivity, or ATPase activity. These initial defects activate expression of a series of intermediary molecular changes, such as altered transcriptomics and/or signaling pathways. These changes then induce histological and morphological changes in the myocardium, such as myocyte hypertrophy and fibrosis, which lead to the clinical features of HCM, such as cardiac arrhythmias and heart failure.

Genetic testing has proved clinically valuable for diagnosing HCM. Most commonly, HCM is due to mutations in sarcomeric genes; however, in a small percentage of cases HCM is the consequence of mutations in some non-sarcomeric genes including inborn errors of metabolism, neuromuscular diseases, mitochondrial diseases, malformation syndromes, and drug reactions that mimic HCM. The majority of HCM cases are found to be due to mutations in the genes for myosin-binding protein C (MYBPC3; 50%), and beta-myosin heavy chain (MYH7; 33%). Other genes that are less commonly causative include cardiac troponin T (TNNT2; 4%), cardiac troponin I (TNNI3; 5%), alpha-tropomyosin (TPMI; <3%), α-cardiac actin (ACTC <3%), essential myosin light chain (MYL3; <3%), regulatory myosin light chain (MYL2; <3%), cardiac troponin C (TNNC1; <1%), α-myosin heavy chain (MYH6; rare), titin (TTN; rare) and several others. HCM can also be caused by metabolic or storage disorders such as Fabry disease (GLA gene), Danon disease (LAMP2gene), and Wolf-Parkinson-White syndrome associated with variants in the PRKAG2 gene and familial transthyretin amyloidosis (TTR gene). More than 1,400 mutations in HCM associated genes have been identified to date. The majority of the mutations in HCM are missense, insertion/deletion and frameshift mutations.

  • Aids in the diagnosis of familial hypertrophic cardiomyopathy
  • To differentiate hereditary Hypertrophic cardiomyopathy associated with mutations in sarcomeric genes from syndromic disorders (i.e. Danon disease, Fabry disease, Noonan syndrome, Pompe disease, Amyloidosis)
  • To provide a comprehensive genetic evaluation for patients with a personal or family history suggestive of hypertrophic cardiomyopathy
  • To identify a pathogenic variant within a gene known to be associated with disease
  • Establishing a diagnosis of a hereditary hypertrophic cardiomyopathy, and in some cases, allowing for appropriate management and surveillance for disease features based on the gene involved

At least one known pathogenic gene or novel mutation associated with HCM should be detected. The finding of a pathogenic variant is supportive of a diagnosis of a hereditary form of cardiomyopathy; however, results should be correlated with clinical findings.

When a pathogenic mutation is identified in a family member, the genetic status of all other relatives can be interrogated; those who did not inherit the genetic abnormality found in the proband have a very low risk for developing the disease If the genetic test in the proband is negative for a sarcomere mutation, or alternatively a novel DNA sequence variant for which pathogenicity is unresolved (i.e., “variant of unknown significance”) is reported, then this testing strategy cannot be applied to determine whether other relatives are genetically affected.

Negative for pathogenic variants for hereditary form of cardiomyopathy

Targeted next-generation sequencing followed by polymerase chain reaction (PCR) and supplemental Sanger sequencing for confirmation if indicated.

Whole blood (EDTA), Extracted DNA, Buccal Swab or Saliva.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
Creatine phosphokinase, Creatine kinase (CK), CK-MB, lactate dehydrogenase (LDH), troponin T, myosin light chain-1 (MLC-1), electrocardiogram, chest X-ray, exercise stress echocardiography, cardiac catheterization and magnetic resonance imaging (MRI).
3-4 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login